The top 100 venture investors in biopharma today. Who's staying at the deals table?
Remember how good 2020 was for biotech venture numbers? Now hold that thought.
Diving into the numbers for life science venture investors last year, DealForma’s Chris Dokomajilar tracked a dramatic downturn in 2022, setting the stage for a new normal that puts healthcare back at levels registered in 2019 and 2020.
But biopharma was singled out for some rough handling once you break them out of the pack. In his annual look at the top 100 investors in biotech, Dokomajilar found that close to $20 billion of the $51 billion in life sciences investments tracked last year were directed at platforms and therapeutics.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.